Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Price, Quote, News and Overview

NASDAQ:PTIX - Nasdaq - US74365N2027 - Common Stock - Currency: USD

0.257  -0.03 (-10.73%)

Premarket: 0.2564 0 (-0.23%)

PTIX Quote, Performance and Key Statistics

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (4/16/2025, 8:00:01 PM)

Premarket: 0.2564 0 (-0.23%)

0.257

-0.03 (-10.73%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.87
52 Week Low0.18
Market Cap1.94M
Shares7.53M
Float6.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO12-18 1996-12-18


PTIX short term performance overview.The bars show the price performance of PTIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

PTIX long term performance overview.The bars show the price performance of PTIX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PTIX is 0.257 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -80.08%.

PROTAGENIC THERAPEUTICS INC / PTIX Daily stock chart

PTIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 16.96 303.70B
AMGN AMGEN INC 14.26 151.96B
GILD GILEAD SCIENCES INC 22.75 130.75B
VRTX VERTEX PHARMACEUTICALS INC 1675.48 124.91B
REGN REGENERON PHARMACEUTICALS 12.04 60.05B
ARGX ARGENX SE - ADR 314.22 35.70B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 29.98B
ONC BEIGENE LTD-ADR N/A 24.58B
BNTX BIONTECH SE-ADR N/A 23.62B
NTRA NATERA INC N/A 20.30B
SMMT SUMMIT THERAPEUTICS INC N/A 17.00B
BIIB BIOGEN INC 7 16.87B

About PTIX

Company Profile

PTIX logo image Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). The company operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Company Info

PROTAGENIC THERAPEUTICS INC

149 Fifth Avenue, Suite 500

New York City NEW YORK 10010 US

CEO: Garo H. Armen

Employees: 2

Company Website: https://protagenic.com/

Investor Relations: https://protagenic.com/investor/sec-filings/

Phone: 12129948200

PROTAGENIC THERAPEUTICS INC / PTIX FAQ

What is the stock price of PROTAGENIC THERAPEUTICS INC today?

The current stock price of PTIX is 0.257 USD. The price decreased by -10.73% in the last trading session.


What is the ticker symbol for PROTAGENIC THERAPEUTICS INC stock?

The exchange symbol of PROTAGENIC THERAPEUTICS INC is PTIX and it is listed on the Nasdaq exchange.


On which exchange is PTIX stock listed?

PTIX stock is listed on the Nasdaq exchange.


What is PROTAGENIC THERAPEUTICS INC worth?

PROTAGENIC THERAPEUTICS INC (PTIX) has a market capitalization of 1.94M USD. This makes PTIX a Nano Cap stock.


How many employees does PROTAGENIC THERAPEUTICS INC have?

PROTAGENIC THERAPEUTICS INC (PTIX) currently has 2 employees.


What are the support and resistance levels for PROTAGENIC THERAPEUTICS INC (PTIX) stock?

PROTAGENIC THERAPEUTICS INC (PTIX) has a resistance level at 0.38. Check the full technical report for a detailed analysis of PTIX support and resistance levels.


Should I buy PROTAGENIC THERAPEUTICS INC (PTIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROTAGENIC THERAPEUTICS INC (PTIX) stock pay dividends?

PTIX does not pay a dividend.


When does PROTAGENIC THERAPEUTICS INC (PTIX) report earnings?

PROTAGENIC THERAPEUTICS INC (PTIX) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of PROTAGENIC THERAPEUTICS INC (PTIX)?

PROTAGENIC THERAPEUTICS INC (PTIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).


What is the Short Interest ratio of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

The outstanding short interest for PROTAGENIC THERAPEUTICS INC (PTIX) is 1.86% of its float. Check the ownership tab for more information on the PTIX short interest.


PTIX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PTIX. When comparing the yearly performance of all stocks, PTIX is a bad performer in the overall market: 95.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PTIX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to PTIX. The financial health of PTIX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTIX Financial Highlights

Over the last trailing twelve months PTIX reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 0.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -282.49%
ROE -545.33%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%34.21%
Sales Q2Q%N/A
EPS 1Y (TTM)0.96%
Revenue 1Y (TTM)N/A

PTIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to PTIX. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners5.42%
Ins Owners12.8%
Short Float %1.86%
Short Ratio0.05
Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A